Bernstein Harold
Reporting owner on Forms 3, 4 and 5, CIK 2050172.
Bernstein Harold reported on 1 issuer in 1 filing, the latest a Form 4 filed 2026-10-02.
Issuers
| Issuer | Roles in the latest filing | Filings | Last filed |
|---|---|---|---|
| Maze Therapeutics, Inc. CIK 1842295 | officer (President, R&D & CMO) | 1 | 2026-10-02 |
Transactions and holdings
Every row of the person's Forms 3, 4 and 5, newest first, with the price and the amount owned after the row as filed.
| Security | Date | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| Maze Therapeutics, Inc. Common Stock | 2026-10-01 | M exercised | +16,141 | $10.42 | 16,141 | Form 4 |
| Maze Therapeutics, Inc. Common Stock | 2026-10-01 | S sold | -16,141 | $26.9341 | 0 | Form 4 |
| Maze Therapeutics, Inc. Stock Option (Right to Buy), derivative | 2026-10-01 | M exercised | -16,141 | $0 | 144,521 | Form 4 |
Filings
The person's Forms 3, 4 and 5, and any 13D or 13G naming it.
| Filing | Subject | Filed | Accepted | Ingested |
|---|---|---|---|---|
| Form 4 0002050172-26-000038 | Maze Therapeutics, Inc. | 2026-10-02 |